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The conformational properties of trypsin-like proteases and
their zymogen forms remain controversial because of a lack of
sufficient information on their free forms. Specifically, it is
unclear whether the free protease is zymogen-like and shifts to
its mature form upon a ligand-induced fit or exists in multiple
conformations in equilibrium from which the ligand selects the
optimal fit via conformational selection. Here we report the
results of 19F NMR measurements that reveal the conforma-
tional properties of a protease and its zymogen precursor in the
free form. Using the trypsin-like, clotting protease thrombin as a
relevant model system, we show that its conformation is quite
different from that of its direct zymogen precursor prethrom-
bin-2 and more similar to that of its fully active Na-bound
form. The results cast doubts on recent hypotheses that free
thrombin is zymogen-like and transitions to protease-like forms
upon ligand binding. Rather, they validate the scenario emerged
from previous findings of X-ray crystallography and rapid kinet-
ics supporting a pre-existing equilibrium between open (E) and
closed (E*) forms of the active site. In this scenario, prethrom-
bin-2 is more dynamic and exists predominantly in the E* form,
whereas thrombin is more rigid and exists predominantly in the
E form. Ligand binding to thrombin takes place exclusively in
the E form without significant changes in the overall conforma-
tion. In summary, these results disclose the structural architec-
ture of the free forms of thrombin and prethrombin-2, consis-
tent with an E*–E equilibrium and providing no evidence that
free thrombin is zymogen-like.
The trypsin fold defines the structural architecture of a
mature “active” protease and its immature “inactive” zymogen
precursor and has been studied in considerable detail, both
functionally and structurally (1–3). The zymogen-to-protease
transition is described by the Huber–Bode mechanism (4) and
involves a proteolytic cleavage at a conserved Arg residue in the
so-called activation domain, followed by insertion of the new N
terminus into the protein core and folding of the active site. The
mechanism was originally assumed to generate a fully func-
tional protease from its inactive zymogen precursor, but this
view proved too simplistic when structures of trypsin-like pro-
teases started to accumulate in the Protein Data Bank (PDB).
The trypsin fold has long been assumed to be mostly “rigid”
(5–8). However, the entire “west wall” of the active site defined
by the amino acid segment at positions 215–217 adopts differ-
ent conformations that open and close access to the primary
specificity pocket at the bottom of the active-site region. This
conformational plasticity is of functional significance (9). In the
open conformation (E), the active site enables ligand binding
with high affinity. In the closed conformation (E*), no binding is
possible. The active site is occluded by collapse of the side chain
of Trp215 and a shift of the backbone of the segment at positions
215–217. The aperture leading to the primary specificity pocket
and defined by the C–C distance of residues Gly193 and
Gly216 changes from 12 Å in the E form to only 8.1 Å in the E*
form (10). In the D216G mutant of I-tryptase (11), chymot-
rypsinogen (12), and the thrombin precursor prethrombin-2
(13), both the E and E* forms are detected in the same crystal.
Independent support of alternative conformations for the free
form of protease and zymogen comes from rapid kinetics stud-
ies of ligand binding to the active site. The mechanism of rec-
ognition for small tripeptides is consistent with a pre-existing
E*–E equilibrium of conformational selection rather than
induced fit (10, 14). The E* form prevails in the zymogen and
gradually shifts to the E form during transition to the mature
protease (15). In fact, the E*–E equilibrium complements the
Huber–Bode mechanism and contributes to organization of
the active site for efficient binding and catalysis (16).
Although evidence of the E*–E equilibrium from the current
structural database (9, 17, 18) and rapid kinetics (10, 14, 15, 17)
is solid, direct proof that such conformational plasticity exists
in solution remains elusive. Structural features revealed by
X-ray may be biased by crystal packing or by the extreme solu-
tion conditions often necessary to achieve crystallization.
Kinetic experiments provide unequivocal evidence of confor-
mational selection only when certain conditions are met for the
observed relaxation rates (19). Previous NMR studies on the
clotting protease thrombin in different bound states (20) have
identified a progressive rigidification of the enzyme upon liga-
tion. From these studies, Huntington (21) and Krishnaswamy
and co-workers (22) have concluded that thrombin is inher-
ently plastic and shuttles within an ensemble of conformations
that are disordered and zymogen-like when free but rigid and
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protease-like when bound (21, 22). However, this ensemble view of
thrombin (20–22) remains a speculation largely inconsistent with
existing X-ray (9, 17, 18) and rapid kinetics (10, 14, 15, 17) data and
lacks validation from NMR studies of free thrombin or of the
zymogen precursor prethrombin-2. Whether free thrombin is
zymogen-like and switches to the mature conformation by
induced fit or pre-exists in alternative conformations from which
the ligand selects the optimal fit can only be established by studies
of the free form. Recent NMR measurements by the Komives
group (23) have targeted the “apo-form” of thrombin using the
S195M mutant and compared the dynamics with those of throm-
bin bound at the active site (24). However, these studies have been
carried out in the presence of Na and therefore describe the
dynamics of ligation of the fully active Na-bound form of throm-
bin rather than its free form.
In this study, we investigate for the first time the conforma-
tion of the protease thrombin and its zymogen precursor pre-
thrombin-2 in the free form using 19F NMR. We labeled all nine
Trp residues in thrombin and prethrombin-2 to interrogate the
conformational properties of the protein in the absence of any
added ligand and Na. 19F NMR has been used for a number of
biologically important systems (25–29) and is ideally suited for
studying the Trp residues of thrombin that are known to report
on changes linked to the E*–E equilibrium, the zymogen-to-
protease conversion, and ligand binding (14, 15, 30).
Results
19F labeling
We labeled all Trp residues of thrombin and prethrombin-2
at the 5 position of the indole ring with 19F and solved the X-ray
structures at 2.3 and 2.1 Å resolution, respectively (Table 1).
The nine Trp residues are distributed over the entire surface
and function as effective reporters of the conformational state
of the protein. The structures show all Trp residues correctly
labeled without significant perturbation of the overall architec-
ture (Fig. 1). Extra density detected at the 5 position of the
indole ring in all cases supports uniform labeling of the reagents
used for NMR studies (Fig. 2). The 19F-labeled prethrombin-2
structure features a conformation of the active site similar to
that of WT (13) (RMSD  0.33 Å). The 19F-labeled thrombin
structure bound to the active site inhibitor PPACK and Na is
very similar to the unlabeled complex (8, 37) (RMSD  0.41 Å).
19F NMR measurements
Having established uniform 19F labeling by X-ray crystallog-
raphy, we proceeded to collect 1D 19F NMR spectra for throm-
bin and prethrombin-2 in the free form, devoid of ligands
bound to the active site or Na. These conditions have not been
explored in previous studies (20, 23, 24) but are essential to
determine the intrinsic properties of the protein in the free
form. Overall, the 1D 19F spectra show seven well-dispersed
peaks for thrombin and only four for prethrombin-2 (Fig. 3A
and Table 2). The most striking differences between zymogen
and protease are the resonance at 43.5 ppm for thrombin not
seen in prethrombin-2, and the range between 47.2 and
49.0 ppm where thrombin shows four distinct peaks, but pre-
thrombin-2 features only two, one large and broad (47.9 ppm)
and the other smaller (48.6 ppm). A sharp resonance ob-
served in prethrombin-2 around 49.8 ppm is replaced by a
smaller one in thrombin, slightly shifted to 49.4 ppm. The
Table 1
Crystallographic data for 19F-labeled prethrombin-2 and PPACK-inhibited thrombin
PDB entry 6V5T 6V64
Buffer/salt 0.1 M HEPES, pH 7.0 0.2 M sodium/potassium tartrate, pH 7.5
PEG 8000 (25%) 3350 (14%)
Data collection
Wavelength (Å) 1.54 1.54
Space group P21 P21212
Unit cell dimensions (Å) a  44.5, b  58.9, c  52.4,   98.4 a  61.9, b  86.6, c  50.5
Molecules/asymmetric unit 1 1
Resolution range (Å) 40–2.1 40–2.3
Observations 79,521 62,626
Unique observations 15,696 12,020
Completeness (%) 99.3 (97.0) 94.9 (84.5)
Rsym (%) 7.3 (55.9) 11.5 (33.4)
I/(I) 18.0 (2.4) 11.7 (2.4)
Refinement
Resolution (Å) 40–2.1 40–2.3
Rcryst, Rfree 0.177, 0.230 0.197, 0.277
Reflections (working/test) 14,911/772 11,333/588
Protein atoms 2,356 2,283
Solvent molecules 103 108
PPACK 1
Na 2
RMSD bond lengths (Å)a 0.008 0.010
RMSD angles (°)a 1.5 1.8
RMSD B (Å2) (mm/ms/ss)b 3.21/2.98/3.50 2.04/2.20/2.08
Protein 41.5 43.6
Solvent 42.6 40.6
PPACK 32.3
Na 33.8
Ramachandran plot (%)
Most favored 95.0 95.0
Generously allowed 5.0 5.0
Disallowed 0.0 0.0
a RMSD from ideal bond lengths and angles and RMSD in B-factors of bonded atoms.
b mm, main chain–main chain; ms, main chain–side chain; ss, side chain–side chain.
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presence of well-defined and separable peaks in thrombin as
opposed to prethrombin-2 suggests that most of the Trp resi-
dues in the zymogen experience a similar chemical environ-
ment. However, this conclusion is not supported by the crystal
structure (Fig. 1) where some Trp residues are exposed to sol-
vent (Trp60d, Trp148, and Trp215) and others are more buried
(Trp51). An alternative explanation is that Trp residues in pre-
thrombin-2 exchange among multiple conformations leading
to broad, overlapping linewidths. Hence, thrombin likely
explores a smaller conformational space and is intrinsically
more rigid than its zymogen precursor prethrombin-2. The
observation points out significant differences between protease
and zymogen in the free form and does not support recent
claims of free thrombin being zymogen-like (20 –22, 24). In
fact, free thrombin is way more similar to its Na-bound form
(Fig. 3B) than its zymogen precursor prethrombin-2 (Fig. 3A).
Rapid kinetics studies suggest that a significant fraction of
the free enzyme exists in the E form (10). Structural studies
document almost complete overlap between the free and bound E
forms (37, 38). The addition of Na is known to boost the catalytic
activity of the enzyme (39) and to rigidify the structure (20, 40).
The 19F NMR spectra in Fig. 3B show that binding of Na sharp-
ens and better separates the peaks of free thrombin and removes
the peak at 47.9 ppm. We conclude that free thrombin is not
zymogen-like. Rather, it is quite distinct from its zymogen precur-
sor prethrombin-2 and already contains features of its more rigid,
Na-bound form as predicted by a mechanism of conformational
selection (10, 19, 41, 42).
Figure 1. Crystal structures of 19F-labeled prethrombin-2 (A) and PPACK (cyan sticks) inhibited thrombin in the Na-bound (purple ball) form (B) with
the side chains of the nine Trp residues of the protein shown as sticks. Residues Trp51 and Trp215 feature characteristic NMR resonances and dynamics (see
Figs. 4 and 5) and are indicated, along with residues Trp141, Trp148, and Trp60d. The 19F label on the 5 position of the indole ring is clearly visible for all Trp residues
(see also Fig. 2). The two structures are similar to unlabeled prethrombin-2 (13) (RMSD  0.33 Å) and PPACK-bound thrombin (8, 37) (RMSD  0.41 Å), proving
that labeling introduced no bias in the fold. Details of the structures are given in Table 1.
Figure 2. Details of the 19F-labeled Trp residues of prethrombin-2 (A) and thrombin (B), taken from the crystal structures shown in Fig. 1 (see also
Table 1). Extra density on the 5 position of the indole side chain is clearly detected for all nine Trp residues, demonstrating that labeling was uniform. The
electron density 2Fo  Fc map (green mesh) is contoured at 1 .
19F NMR of thrombin
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Resonance assignment
Given the differences between zymogen and protease in the
free form, we turned our attention to the specific Trp residues
responsible for the observed changes. Assignments of the nine
Trp residues in both thrombin and prethrombin-2 (Fig. 4, A
and B) were made from spectra for which each individual Trp
residue was replaced by Phe. The substitution is inconsequen-
tial on the catalytic properties and specificity of thrombin and
has been used to identify the fluorophores responsible for Na
binding to the enzyme (30). Assignment of individual Trp res-
idues was often complicated by the lack of selective perturba-
tion of peaks in the WT spectrum. In the case of prethrombin-2,
the W215F substitution affects both the large peak around
47.9 ppm and the peak at 49.8 ppm, almost 2 ppm apart
(Fig. 5A). This suggests that Trp215 exists in alternative confor-
mations that exchange very slowly. Mutations of Trp60d, Trp96,
Trp141, Trp148, Trp207, and Trp215 result in perturbation of the
peak at 47.9 ppm (Fig. 4A). Residues Trp51 and Trp237 map to
the peaks at 46.7 and 48.6 ppm, respectively, but Trp29 and
Trp207 could not be assigned. In the case of thrombin (Fig. 4B),
clustering is less pronounced, and residues Trp141, Trp51,
Trp215, Trp96, and Trp237 could be assigned to resonances at
43.5, 46.7, 47.5, 47.9, and 49.4 ppm, respectively (see
Fig. 5B for W215F). The relative solvent exposure of these res-
idues is consistent with the crystal structure (8, 43) (see also Fig.
1B). Trp51 maps to the same resonance position as in prethrom-
bin-2 (Fig. 4A), but Trp237 is shifted upfield. Of the remaining
four Trp residues, Trp29 and Trp207 could not be assigned,
whereas Trp148 and Trp60d cluster in the peaks within the range
of 47 to 48 ppm and could not be separated, suggesting
similar solvent exposure as seen in the crystal structure (8, 43)
(see also Fig. 1B). We conclude that prethrombin-2 is more
dynamic than thrombin, with most of its Trp residues in slow
exchange between alternative conformations and experiencing
an environment that changes significantly during the conver-
sion to thrombin.
Residue dynamics
Individual resonances could be assigned to residues Trp51
and Trp215 in thrombin and Trp51 in prethrombin-2. These
residues were investigated further by measurements of T1, T2 ,
and CPMG relaxation dispersion to gain insight into their range
of motions. Trp51 is positioned 33 Å away from the Na binding
site and 22 Å away from the catalytic Ser195 (Fig. 1). The peak
for Trp51 has the same resonance position at 46.6 ppm in both
thrombin and prethrombin-2 (Fig. 4) and broadens from 0.27 to
0.37 Hz relative to thrombin bound to Na (Fig. 6), suggesting
the presence of multiple conformations. Indeed, the peak
shows a distinct relaxation dispersion profile indicative of con-
formational exchange, especially in prethrombin-2 (Figs. 7 and
8). Collection at a second field of 600 MHz allowed relaxation
dispersion curves at both fields to be fit to a two-state model
in the fast-exchange regime (44) with kex  19,000  1,000 s1
in thrombin and kex  2,970  20 s1 in prethrombin-2 (Fig. 9).
The intrinsic dynamics of Trp51 indicate faster exchange in
thrombin than prethrombin-2. Interestingly, the exchange in
thrombin is completely abrogated upon Na binding (Fig. 8),
suggesting rigidification of a residue located 33 Å away. The
slower exchange at Trp51 observed in prethrombin-2 is indica-
tive of the presence of more large-scale motions compared with
thrombin. These findings add complexity to the scenario
emerged from the X-ray structural database where the confor-
mation of Trp51 is essentially the same in prethrombin-2 (13)
and thrombin free or bound to ligands (37). We conclude that
Na binding has long-range effects on the structure of throm-
bin and that Trp51 is allosterically coupled to regions affected by
the zymogen to protease conversion, as well as Na binding,
thereby establishing a new allosteric pathway of communica-
tion within the protein that affects widely separated residues.
Residue Trp215 defines the P3 site of recognition for sub-
strate binding to the active site (8) and exists in different con-
formations that open and close access to the active site accord-
ing to the X-ray structural database (9, 18). The role of the
indole side chain of Trp215 in the E*–E equilibrium has been
Figure 3. Overlay of 1D NMR spectra between prethrombin-2 and thrombin (A) and between free thrombin and thrombin bound to Na (B). The
spectra show how free thrombin is more similar to its Na-bound form than the zymogen precursor prethrombin-2. The difference is particularly noticeable in
the number of separate peaks detected for zymogen and protease, consistent with a more rigid structure for the latter.
Table 2
19F chemical shifts (ppm) of Trp residue
ND, not determined.
Thrombin Prethrombin-2
Trp29 ND ND
Trp51 46.7 46.7
Trp60d 48.5, 48.7 47.9
Trp96 47.9 47.9
Trp141 43.5 47.9
Trp148 48.5 47.9
Trp207 ND 47.9
Trp215 47.5 47.9, 49.8
Trp237 49.4 48.6
19F NMR of thrombin
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tested by rapid kinetics with the W215A mutation and found
not to be responsible for the opening and closing of access to
the primary specificity pocket (14). Specifically, the W215A
mutant binds ligands at the active site with a mechanism of
conformational selection as WT, proving that removal of the
side chain of Trp215 does not equalize access to the active site
between the E* and E forms. The role of the side chain of Trp215
is to keep the active site open and slow down the E3 E* con-
version by establishing an interaction with the benzene ring of
Phe227 (14). Once this hydrophobic interaction is disrupted,
closure of the active site in the E* form is faster and results in
reduced catalytic activity (45, 46). The rate of exchange
between E* and E in thrombin and prethrombin-2 becomes of
interest. Trp215 maps to a single peak at 47.5 ppm in thrombin
(Figs. 4B and 5B). In prethrombin-2, Trp215 maps with other
residues to the broad peak in the range of 47 to 48 ppm and
also to a unique peak close to 49.8 ppm (Figs. 4A and 5A). The
presence of two peaks separated by a large chemical shift indi-
cates that Trp215 features two distinct conformations that
exchange very slowly or not at all in prethrombin-2 (Fig. 7). The
Figure 4. 1D NMR spectra of prethrombin-2 (A) and thrombin (B) with peaks assigned from single site replacement of Trp with Phe (see also Fig. 5). The
substitution does not change the functional properties and specificity of thrombin (30). A, assignment of individual Trp residues in prethrombin-2 often did not
result in selective perturbation of peaks in the spectrum (Fig. 3A). The W215F replacement affected both the large peak around 47.9 ppm and the peak at
49.8 ppm (Fig. 5). Mutations of Trp60d, Trp96, Trp141, Trp148, Trp207, and Trp215 perturbed the peak at 47.9 ppm, and those of Trp51 and Trp237 affected the
peaks at 46.7 and 48.6 ppm, respectively. Trp29 and Trp207 could not be assigned. B, clusters are less pronounced than in prethrombin-2. Mutations of
Trp141, Trp51, Trp215, Trp96, and Trp237 mapped to peaks at 43.5, 46.7, 47.5, 47.9, and 49.4 ppm, respectively. Trp51 mapped to the same resonance
position as in prethrombin-2, but Trp237 was shifted upfield. Of the remaining four Trp residues, Trp29 and Trp207 could not be assigned, and Trp148 and Trp60d
clustered in the peaks in the range of 47 to 48 ppm and could not be separated.
Figure 5. Overlay of 1D NMR spectra between WT (blue) and mutant
W215F (red) for prethrombin-2 (A) and thrombin (B). Asterisks indicate the
region of the spectrum perturbed by the single-site replacement.
Figure 6. Overlay of resonances for Trp51 in prethrombin-2, free throm-
bin, and thrombin bound to Na indicating distinct line broadening of
Trp51.
Figure 7. CPMG relaxation dispersion profiles in the fast time-scale
regime of residues Trp51 (filled circles) and Trp215 (open circles) in pre-
thrombin-2 (A) and thrombin (B).
19F NMR of thrombin
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dynamic profile changes upon transition to thrombin and sup-
ports fast exchange between two states (Fig. 7). Measurements
at different field strength (Fig. 9) yield a rate of exchange kex 
7,980  90 s1. Although the structural database documents a
similar behavior for Trp215 in zymogen and protease with
regard to the E* and E forms controlling access to the primary
specificity pocket (9, 18), the dynamics of Trp215 are consistent
with an exchange considerably faster in thrombin than
prethrombin-2.
Discussion
Our understanding of the conformational nature of trypsin-
like proteases and their zymogens has been deeply influenced
by the celebrated Huber–Bode mechanism of zymogen activa-
tion (4). Activity is assumed to result from proteolytic cleavage
of a conserved Arg residue in the activation domain followed
by an ionic interaction that is established between the new N
terminus of Ile16 and the side chain of the highly conserved
Asp194. The newly formed H-bond between Ile16 and Asp194
organizes the oxyanion hole around Gly193 and the catalytic
Ser195 and the primary specificity pocket around Asp189. This
transition, however, is neither necessary nor sufficient to gen-
erate a fully active protease. Activity can be triggered by alter-
native mechanisms. Single-chain tissue-type plasminogen
activator features catalytic activity by establishing an in-
tramolecular H-bond that produces the same structural tran-
sitions as the Huber–Bode mechanism (47). A similar strategy
is used by the plasminogen activator in the saliva of Desmodus
rotundus (48). Bacteria have evolved proteins like streptokinase
(49) and staphylocoagulase (50) that can activate the host
fibrinolytic and coagulation cascades without proteolytic cleav-
age of their target zymogens plasminogen or prothrombin. An
entire class of zymogen activator peptides mimicking strepto-
kinase and staphylocoagulase has been developed by phage dis-
play (51). The Huber–Bode mechanism also appears not to be
sufficient for protease function. A pre-existing equilibrium
between closed (E*) and open (E) conformations of the active
site controls the onset of substrate binding and catalysis (15). In
the E* form, substrate cannot bind to the active site, and catal-
ysis is impeded. Importantly, the balance between E* and E
changes between zymogen and protease, with the E* form pre-
dominating in the former (15, 16) and presaging little overlap
between the free forms of protease and its zymogen precursor.
The results reported in this study offer a view of the struc-
tural architecture of thrombin and prethrombin-2 in the free
form that is entirely consistent with the E*–E equilibrium. We
find no evidence that free thrombin is zymogen-like, as specu-
lated in previous functional (20 –22) and computational (52)
studies. Labeling all nine Trp residues of the protein for 19F
NMR measurements show that free thrombin is quite different
from prethrombin-2 and more similar to its Na-bound form,
in agreement with the structural differences between E* and E
(17, 37), the predominance of E* for prethrombin-2 and of E for
thrombin (10, 17, 19), and the fact that E form changes little
upon ligand binding (17, 38).
Our 19F NMR data provide information on the dynamics of
critical Trp residues of the protein. Most of these residues can-
not be assigned in the 1D 19F NMR spectrum of prethrombin-2
because of overlap of linewidths. Trp51 maps to a single peak
and features rapid exchange between alternative conforma-
tions in both prethrombin-2 and thrombin. Trp215 maps to two
widely separated peaks, indicating a very slow exchange
between alternative conformations. When prethrombin-2
transitions to thrombin upon activation, the overall structure
becomes less dynamic, with several individual peaks in the 1D
19F NMR spectrum that can be assigned to specific Trp resi-
dues. Unlike Trp51, residue Trp215 features distinct dynamics
from prethrombin-2 and exchanges rapidly between alternative
conformations with kex  7,980  90 s1, which is significantly
faster than the rate for the E*–E exchange detected by rapid
kinetics (10, 15). Although the dynamic nature of Trp215 (Fig.
5B) is consistent with alternative conformations documented
by the structural database (9, 17, 18), its fast time scale of
exchange points to events that eventually do not influence
access to the active site as documented in the E*–E equilibrium.
Indeed, removal of the indole of Trp215 with the W215A sub-
stitution changes little the E*–E distribution compared with
WT thrombin (14, 53). Other features of the protein, like move-
ment of the backbone of the 215–217 segment, may be respon-
sible for the E*–E equilibrium (10) and should be investigated
further by NMR of the free form to extend the work reported in
this study.
Materials and methods
Reagents
Prethrombin-2 cloned into a pet28 Escherichia coli expres-
sion vector was transformed into the BL21DE3 E. coli strain.
50-ml starter cultures in LB supplemented with ampicillin were
grown for up to 16 h at 37 °C in an orbital shaker rotating at 225
rpm. Starter cultures were diluted 1:50 in LB, also supple-
mented with ampicillin, and grown for a further 3– 4 h until
A600  1.0 was reached. The growth culture was spun down at
4,000 rpm for 20 min. The pellet was then dissolved in minimal
medium for incorporation of 5-F-Trp and grown for an addi-
tional 2 h before recombinant protein expression was induced
by adding 1 mM isopropyl -D-thiogalactopyranoside and
growing at 25 °C overnight. The formulation for 5-F-Trp min-
imal media reads as 50 mM Na2HPO4, 25 mM KH2PO4, 20 mM
Figure 8. Field-dependent 19F CPMG relaxation dispersion data for Trp51
in prethrombin-2 (filled circles), free thrombin (open circles), or thrombin
bound to Na (half-filled circles).
19F NMR of thrombin
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NH4Cl, 100 g/ml ampicillin, 0.25 mg/liter 5-F-Trp, and 0.4%
w/v D-glucose.
For inclusion body purification and refolding, the cells were
pelleted by centrifugation at 4,000 rpm for 25 min and resus-
pended in 50 mM Tris, pH 7.4, 20 mM EDTA, 1 mM DTT, and 1%
Triton X-100. The cells were lysed using an Avestin C3 emul-
sified or sonicator. Inclusion bodies were separated by centrif-
ugation at 10,000 rpm for 15 min. Inclusion bodies were washed
sequentially in 50 mM Tris, pH 7.4, 20 mM EDTA, and 1 M NaCl
followed by 50 mM Tris, pH 7.4, and 20 mM EDTA. Inclusion
bodies were solubilized in 40 ml of 7 M guanidine HCl and
homogenized using a Dounce homogenizer. Inclusion bodies
were centrifuged at 10,000 rpm for 10 min to remove insoluble
material. Inclusion bodies were refolded by dilution into 50
excess of 50 mM Tris, 500 mM NaCl, 1 mM EDTA, 10% glycerol,
600 mM Arg, 0.2% Brij58, 1 mM L-Cys, pH 8.3. Inclusion bodies
were incubated at 25 °C overnight.
Properly folded prethrombin-2 was purified using a heparin-
affinity column and buffer-exchanged through a size-exclusion
column or 10-kDa Centricon into a final NMR buffer formula-
tion of 20 mM Tris, 700 mM NaCl, or 700 mM choline chloride,
50 mM Arg, and 10% trehalose. Thrombin was generated from
prethrombin-2 using ecarin and exchanged into the same NMR
buffer. Protein was concentrated to 	5 mg/ml and spiked with
10% D2O for 19F NMR data collection.
All constructs for NMR data collection contained neutraliza-
tion of the active-site Ser195 with the S195A mutation to pre-
vent autocatalytic degradation and enable collection of relax-
ation dispersion data over a period of days.
19F NMR studies
1D 19F NMR measurements were carried out at 658.780
MHz, 25 °C using a 19F QCI cryoprobe (City University of New
York Advanced Science Research Center Biomolecular NMR
Facility) and a 5-mm PFG quadruple resonance inverse detec-
tion cryoprobe (Saint Louis University High Resolution NMR
Facility). No differences with 1D 19F NMR spectra were
observed between the probes. Relaxation dispersion NMR
experiments were carried out at 658.780 MHz, 25 °C (City Uni-
versity of New York Advanced Science Research Center
Biomolecular NMR Facility) with a 19F QCI cryoprobe and at a
second field strength of 564.686 MHz with a TCI (H/F-CN-D)
cryogenic probe (Wisconsin). All spectra were referenced to
TFA. Typical 1D 19F acquisition parameters were a 20,000-Hz
sweep width (42.5 ppm), 0.35-s acquisition time, 5-s relaxation
delay time, and 5.0-s 90° pulse length. Spectra were processed
with a 20-Hz exponential line broadening using topspin.
Longitudinal (T1) and transverse (T2) 19F relaxation mea-
surements were determined using classic 1D inversion recovery
(T1) and the Carr–Purcell–Meiboom–Gill (CPMG) spin echo
pulse sequence (T2) (31, 32). 19F T1 inversion recovery experi-
ments were acquired at a series of variable delay times (0.0625,
0.125, 0.25, 0.5, 1.0, 2.0, 4.0, and 8.0 s) and a relaxation delay of
7 s. 19F CPMG experiments consisted of a 90x  [cp  180y 
cp] n pulse train acquired with a series of spin-echo evolution
times (e.g. 8 points ranging between 0.5 and 128 ms). Longitu-
dinal and transverse relaxation times were computed by fitting
plots of 19F signal intensity for a given 5-F-Trp residue or peak
as a function of variable decay (T1) or spin-echo times (T2). 19F
CPMG relaxation dispersion experiments in which the trans-
verse relaxation rate, R2, is determined as the function of the
delay between 180° pulses (2cp) were acquired across a series of
cp values (e.g. 50 –500 s) and plotted against CPMG fre-
quency (29). All measurements were collected in duplicate.
X-ray studies
Crystallization of 19F-labeled, WT prethrombin-2, and
thrombin bound to the active site inhibitor H-D-Phe-Pro-Arg-
CH2Cl (PPACK) was achieved at 25 °C by the vapor diffusion
technique, using an Art Robbins Instruments PhoenixTM liquid
handing robot with 6 –10 mg/ml protein (0.3 l) mixed with an
equal volume reservoir solution. Optimization of crystal
growth was achieved by the hanging-drop vapor-diffusion
method mixing 3 l of protein with equal volumes of reservoir
solution (see Table 1). The crystals were grown in 1 week at
25 °C and frozen with 25% glycerol from the original mother
liquor. X-ray diffraction data were collected at 100 K with a
home source (Rigaku 1.2 kw MMX007 generator with VHF
optics) Rigaku Raxis IV2 detector and were indexed, inte-
grated, and scaled with the HKL2000 software package (33).
Structures were solved by molecular replacement using
PHASER from the CCP4 suite (34) and the structures of human
prethrombin-2 mutant S195A (PDB code 3SQH) and human
thrombin in complex with PPACK (PDB code 1PPB) as starting
models. Refinement and electron density generation were per-
formed with REFMAC5 from the CCP4 suite. 5% of the reflec-
tions were randomly selected as a test set for cross-validation.
Model building and analysis were carried out using COOT (35).
Figure 9. Field-dependent CPMG relaxation dispersion profiles in the fast time-scale regime. Filled circles represent transverse relaxation rates (R2) as a
function of cpmg acquired at 658.780 MHz, and open circles represent transverse relaxation rates (R2) as a function of cpmg acquired at 564.686 MHz. The data
were fit to a two-state model in the fast-exchange regime yielding the following: A, residue Trp51 in prethrombin-2, kex  2,970  20 s
1, R2
0 (564.686 MHz) 
204  1 s1, R2
0 (658.780 MHz)  260  0.3 s1. B, residue Trp215 in thrombin. kex  7,980  90 s
1, R2
0 (564.686 MHz)  160  1 s1, R2
0 (658.780 MHz)  258 
1 s1. C, residue Trp51 in thrombin, kex  19,000  1,000 s
1, R2
0 (564.686 MHz)  100  10 s1, R2
0 (658.780 MHz)  140  10 s1.
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In the final refinement stage, TLS tensors modeling rigid-body
anisotropic temperature factors were calculated and applied to
the model for the 19F-labeled thrombin bound to PPACK. Ram-
achandran plots were calculated using PROCHECK (36). The
statistics for data collection and refinement are summarized in
Table 1.
Data availability
Atomic coordinates and structure factors for the two structures
reported in the manuscript have been deposited in the PDB (acces-
sion code 6V5T for 19F-labeled prethrombin-2 and accession code
6V64 for 19F-labeled thrombin bound to PPACK). All other data
described in the manuscript are contained within the manuscript.
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